Alfa Thermodiagnostics, Inc. has engineered a next-generation Whole-Body Thermometry adjunct diagnostic tool that provides a visible measurement of the Autonomic Nervous System, often the key to the causal factors of many diseases. The AlfaSight 9000™ is grounded in the established science of Regulation Thermography which was invented and first commercialized in Germany more than 20 years ago. It is a proven, accurate technology supported by more than 100,000 patient assessments, and has been clinically correlated with hundreds of MRI & CT Scans.
Dr. Daniel Beilin led the US FDA clearance of first-generation Regulation Thermography technology in 1996 and now has successfully led Alfa’s upgraded device FDA clearance. He is recognized worldwide as the foremost authority on Whole-Body Thermometry, and is supported by leaders in the fields of Radiology, Neurobiology, and Regulation Medicine.
The AlfaSight 9000™ is a non-invasive patient assessment tool that identifies a wide range of physiological dysfunction by analyzing skin temperature changes over time. As an adjunct technology to mammography and other anatomical imaging devices, it can dramatically improve the accuracy of routine testing for a wide range of impaired health conditions.
The AlfaSight 9000TM is a state-of-the-art health testing system that identifies physiological dysfunction very early in the disease process. Using a subtle thermal stress stimulus that initiates a regulation response, underlying disturbances and dysfunctional organ systems are revealed with a high degree of accuracy.
About the product.
This Whole-Body Thermometry System employs the science of Regulation Thermography, and benefits from more than 30,000 patient tests performed with a previous iteration of this technology over the past 2 decades. Disease signatures have been derived from the data and correlated with nuclear-CT (SPECT) and MRI studies that were performed by Dr. David Hickey, Radiologist and Alfa Medical Board member, in his Dallas-based imaging center.
Information provided by the AlfaSight System allows physicians to make more accurate and real-time assessments of the root cause of a disease and accompanying factors. More focused laboratory or imaging tests can then be prescribed for a more efficient and cost-effective approach to diagnosis.
The system also recognizes trends in the body that can assist in the practice of preventive medicine.
Specific areas of physiological dysfunction that can be identified include:
- Abnormalities of the female breast
- Peripheral vascular disease
- Musculoskeletal disorders
- Extracranial cerebral and facial vascular disease
- Abnormalities of the thyroid gland
- Various neoplastic and inflammatory conditions
Parallel disease factors accompanying many conditions such as heart disease, diabetes, cognitive disorders and viral diseases are also identified. Early stage detection of these factors is critical for effective treatment and faster recoveries.
The AlfaSight 9000TM is an adjunct diagnostic device and further clinical tests must be performed to determine diagnosis.
he AlfaSightTM 9000 received 510(K) clearance through the FDA Division of Radiological Health.
Indications for Use
The AlfaSightTM9000 is cleared for marketing and sales in the United States for the adjunct diagnosis of:
- abnormalities of the female breast
- peripheral vascular disease
- musculoskeletal disorders
- extra-cranial cerebral and facial vascular disease
- abnormalities of the thyroid gland
- various neoplastic and inflammatory conditions
The AlfaSightTM9000 is not intended to serve as a sole diagnostic screening procedure. It is intended as an adjunct diagnostic device only. Thermometry is not a replacement for Mammography or any other imaging method, rather it is to be used in conjunction with conventional testing to provide a physiological perspective.